EGFR and lung adenocarcinoma: The efficiency and optimal combination strategies of immune checkpoint inhibitors (ICI) in lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor (EGFR) other mutations apart from 19del/L858R (classical), which account for up to 20% EGFR mutations, remains unclear.